Latest news with #Euronext
Business Recorder
2 days ago
- Business
- Business Recorder
EU wheat eases in US holiday lull
PARIS: European wheat futures edged lower on Friday to ease from a one-week high, with a US holiday depriving the market of usual impetus and favourable harvest prospects and slow exports curbing prices. September wheat on Euronext was 0.8% down at 195.75 euros ($230.60) per metric ton by 1618 GMT. The front-month position was almost unchanged over the week, having fallen to a contract low of 192.75 euros on Tuesday before rebounding to a one-week at 199.25 euros on Thursday as investors adjusted short positions. A slight rise in the euro, which remained near a 3-1/2 year high against the dollar struck earlier this week, also capped Euronext prices. 'The market still faces a bearish combination of good crop prospects in the west EU and Black Sea,' one German trader said. 'Cheap Russian and other Black Sea prices are likely to win export business in the near future. But demand is anyway thin, with importers delaying purchases, expecting prices to fall further if harvest pressure mounts.' New-crop Russian 11.5% protein wheat was quoted on Friday below $220 at around $217-$219 a ton FOB, 12.5% at $224-$226. Ukrainian new crop feed was on Friday quoted as low as 185-195 euros a ton including delivery to north Germany/the Netherlands, he said. There was little reaction to news that the European Commission will offer Ukraine an annual import quota of 1.3 million tons of wheat under a revised trade agreement. The quota, which will cut inflows of Ukrainian wheat compared with the 4-6 million tons imported annually under quota-free access since the start of Russia's invasion, was seen reshuffling trade but with limited price effects. 'It will affect intra-EU trade, with importers in Europe buying more from France or Germany instead of Ukraine,' a French trader said.
NZ Herald
3 days ago
- Business
- NZ Herald
European ESG rebrand challenges NZ ethical investing norms – Fran O'Sullivan
The US President has strong-armed Nato members into increasing their defence budgets to 5% of GDP. However, the Europeans are determined their increased expenditure should boost their own defence companies – not simply be used to buy American military hardware and boost the profits of those American companies contributing to the US war machine. Back here, New Zealand companies have devoted thousands of pages in successive annual reports to trumpeting their prowess on environmental, social and governance metrics (traditional ESG). Some are required by law. Some frankly fall into 'feel-good' box-ticking (often notable among failing companies!) and a deflection from a company's true commercial driver, which is to post a profit and stay in business. It is time for a rethink. As with DEI (diversity, equity and inclusion) policies, which even BlackRock chief executive Larry Fink (a previous champion) has walked away from, there is a sharpening of focus. At the Amsterdam Stock Exchange last week, chief executive René van Vlerken was quick to emphasise that the heightened geopolitical risks – obvious on Europe's backdoor where the Russian-Ukraine conflict verges on a 'forever war' – has made for the more existential approach. The Amsterdam exchange is part of the pan-European stock exchange Euronext, which operates regulated exchanges in Belgium, France, Ireland, Italy, Norway, and Portugal as well as the Netherlands. In May, Euronext's chief executive and chairman Stephane Boujnah said the redefinition of ESG was in response to a 'new geopolitical order'. 'European aerospace and defence companies have expressed the urgent need to invest heavily in their innovation and production capacities to guarantee Europe's strategic autonomy for the next decade,' Boujnah said. Euronext said it would revisit the methodologies for ESG indexes to limit the exclusions currently placed on defence companies. This poses a challenge for traditional ESG ratings agencies when it comes to advertising investments in defence industry-related bonds (for instance). It also has ramifications for entities like the New Zealand Super Fund and KiwiSaver funds, which walk a tightrope on definitions of ethical investing, with all sorts of activists getting exercised over where the funds invest. How will funds approach investing in New Zealand companies ranging from aerospace to quantum computing or drone manufacturing – all within the scope of the Government's new defence plans – when there is a clear implication their products will be used in armed conflict? Euronext has said it will encourage the rating agencies to restrict the concept of controversial weapons solely to armament activities prohibited by relevant international treaties. What's at stake is not small bikkies. European Commission president Ursula von der Leyen believes the EU could mobilise up to €800 billion ($1.55 trillion) to strengthen its defence industry. There are also opportunities for Kiwi companies like Dawn Aerospace, with its dual base in the Netherlands and New Zealand. I was in the Netherlands with 40 business leaders on the New Zealand Initiative think tank's Go Dutch study tour, which was designed to provide insights from small, advanced economies. Fortuitously, our time in the Netherlands coincided with the Nato Summit in the Hague. It also coincided with the US attack on three nuclear facilities in Iran with 'bunker buster' bombs and Tomahawk missiles, which made for frantic rebooking of flights back to New Zealand after some airlines pulled back from flying over the Middle East. Trump did attend Nato, being hosted overnight by the Dutch King and Queen in their personal palace before a truncated Nato meeting. At the summit, the allies made a commitment to investing 5% of GDP annually on core defence requirements and defence and security-related spending by 2035. At least 3.5% of GDP was to fit within agreed definitions of Nato defence expenditure to resource core defence requirements and to meet Nato's Capability Targets. The other 1.5% was to be invested in protecting critical infrastructure; defending networks; ensuring civil preparedness, resilience and innovation; and strengthening the defence industrial base. Prime Minister Christopher Luxon was also in the Netherlands. He was the only political leader from the Indo-Pacific Four – Japan, Australia, South Korea and New Zealand – to attend the Nato Summit. It was noted that he had turned up. Luxon contends he was under no pressure to increase New Zealand's defence spending above the targeted 2% of GDP within the decade that was outlined in the recent Budget. But this is a more dangerous world. It was notable that when we visited Rotterdam – which hosts Europe's largest port and some fully-automated container terminals – that the Dutch Ministry of Defence wants to acquire terminal capacity for handling multiple ships carrying military cargo (mainly equipment and ammunition) simultaneously. It has been agreed within Nato that this type of cargo can be transported via the Netherlands, even if the destination is outside the Netherlands. In the Netherlands, where older Dutch people still hold sharply to the lessons from the Nazi occupation in World War II – and where they have more recently been hurt by soaring energy prices sparked by the withdrawal of Russian gas flowing to Europe via Ukraine – there is a quiet confidence. With 26% of land under sea level, the Netherlands has developed extensive water management systems, including dikes, dams and polders (land reclaimed from the sea) to manage the obvious risk. There is a frank realism there – we could do with a bit more here. Disclaimer: Fran O'Sullivan met her own costs to take part in the New Zealand Initiative's Go Dutch study tour. These are her views.
Al Arabiya
3 days ago
- Al Arabiya
Authorities to attempt to reopen Mosel river in Germany to shipping
Attempts will be made on Friday and over the weekend to reopen the river Mosel in west Germany on a limited scale to inland waterways freight shipping after an accident with a vessel damaged a lock, navigation authorities said on Friday. Shipping was stopped on the river, an important transit route for grains and rapeseed between Germany and France, after an accident involving a passenger vessel on Wednesday damaged a lock at Sankt Aldegund between Koblenz and Trier. Attempts are now starting to see if the lock can still be used for vessel transits on a limited scale after an initial assessment of damage, said a spokesperson for river navigation authority GDWS. The first test transits through the lock could be made over the weekend. If this is not feasible, attempts are planned to reopen the lock with temporary water control barriers. But this would be a slower process than using the damaged lock, possibly with each ship needing around an hour to transit the lock. About 50 inland waterways freighters are currently stranded on the river, called the Moselle in France. First efforts will be concentrated on enabling the stranded ships to pass through the lock to reach their destinations. But the aim is to allow normal sailings to resume, the spokesperson said. It is still not possible to say when the lock can be fully repaired. A similar lock accident on the Mosel in December that halted shipping led futures exchange operator Euronext to suspend physical delivery to river ports in eastern France for its rapeseed futures.
Yahoo
3 days ago
- Business
- Yahoo
IDEX Biometrics ASA – EX. SHARE CONSOLIDATION (REVERSE SPLIT) TODAY
Issuer name: IDEX Biometrics ASA Ex. date: 4 July 2025 Type of corporate action: Share consolidation (reverse split) Previous ISIN: NO0013107490 New ISIN: NO0013536078 For further information contact:Anders Storbråten, CEO and CFOE-mail: anders@ About this noticeThis notice was published by Erling Svela, Vice president of finance, on 4 July 2025 at 08:00 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to Continuing Obligations at Oslo Børs Euronext and is published in accordance with section 5‑12 of the Norwegian Securities Trading Act.
Yahoo
3 days ago
- Business
- Yahoo
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
MARSEILLE, France, July 04, 2025--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as of July 3, 2025: Total number of shares outstanding: 92,183,523 ordinary shares 6,434 Preferred Shares 2016 7,581 Preferred Shares 2017 Total number of theoretical voting rights (1): Total number of exercisable voting rights (2): 92,962,943 92,944,368 (1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. (2) The total number of exercisable voting rights (or "net" voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including "anticipate," "believe," "can," "could," "estimate," "expect," "may," "might," "potential," "intend," "should," "will," or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on Contacts For additional information, please contact: Investors Innate Pharma Henry WheelerTel.: +33 (0)4 84 90 32 Media Relations NewCap Arthur RouilléTel.: +33 (0)1 44 71 00 15innate@
